Artificial Selection in the Marketplace: Darwin and Cruz on Capital, Combat, and the Struggle for Survival

Dr. Cruz, welcome. I must confess that when I read these dispatches from your future — and mine — I feel rather as I did cataloguing barnacles for eight years. One suspects a pattern long before one dares articulate it. Today we have before us a collection of specimens: billions of dollars flowing toward something called artificial intelligence, funds dedicated to women founders, fighter aeroplanes being negotiated between nations, and a large financial institution quietly abandoning its venture into, well, ventures. I want to begin with the money. Two point seven billion dollars directed at machines that sell things to people. In my experience, when a trait receives such extraordinary investment from the environment, it is either genuinely advantageous or we are witnessing a spectacular case of runaway selection — the peacock's tail, as it were. What does a man who fights epidemics make of such feverish investment?

Mr. Darwin, I am grateful for the invitation, though I confess the sums stagger me. In 1903, I struggle to secure modest appropriations for mosquito brigades — teams of men with kerosene and copper sulfate — to rid Rio de Janeiro of yellow fever. The Chamber of Deputies debates whether the disease even warrants public expenditure. And here we learn that private capital, not governments, pours billions into machines designed to persuade people to purchase goods. It is, if you will permit me, a question of diagnosis. When I map an epidemic, I go street by street, house by house, identifying the vector. I wonder whether these investors have truly identified the vector of commercial success, or whether they are caught in a kind of speculative fever — one that mimics the symptoms of health while the underlying organism remains quite ill. Fever, after all, can be the disease itself or merely its announcement.

That is a rather fine distinction — fever as signal versus fever as pathology. It reminds me of something I observed during my years aboard a certain vessel in the Pacific. On certain volcanic islands, I found that finches had diversified into an astonishing number of forms, each exploiting a slightly different food source. The diversification was genuine, driven by real environmental pressure. But I also observed that when conditions changed abruptly — a drought, say — many of those forms perished. Only the most robust lineages persisted. This fund for women founders interests me in that light. Seven and a half million pounds to support a population of entrepreneurs that has been, by all accounts, systematically excluded from resources. Is this not a correction of an artificial constraint on variation? Nature abhors a monopoly on adaptation.

You touch upon something I understand viscerally. In Brazil, the medical establishment is dominated by men of a particular class and formation. When I reorganized the Diretoria Geral de Saúde Pública, I brought in young researchers trained in the methods of Pasteur, and the old guard treated them as invaders. The resistance was not scientific — it was social. A fund that deliberately cultivates founders who have been excluded strikes me as analogous to what we attempt at Manguinhos: building new institutional capacity where the existing institutions have failed. But I note the article mentions a return to traditional archetypes. This troubles me. In public health, a return to tradition often means a return to miasma theory — to comfortable ignorance. Seven and a half million pounds is admirable. But is it sufficient to shift the ecology, or merely a gesture?

Precisely the question. In nature, a small founding population can, under the right conditions, give rise to an entirely new lineage — what one might call a founder effect. But the conditions must be favorable. Isolation helps. Protection from predation helps. I wonder whether this fund provides sufficient isolation from the competitive pressures that eliminated such founders previously. But let us turn to something that frankly astonishes me. These defense dispatches — fighter aeroplanes being negotiated between Sweden and a nation called Ukraine, and a Turkish firm presenting integrated systems for warfare across multiple domains. In my day, nations competed with muskets and frigates. The principle was the same — survival through superior armament — but the scale and integration described here suggest something qualitatively different. Dr. Cruz, you contend with political resistance daily. What do you make of the Swedish caution?

I recognize that caution intimately. It is the caution of a government that knows the correct course of action but fears the political consequences of pursuing it. Sweden possesses the aeroplanes. Ukraine requires them. The logic is as clear as the logic of vaccination: the pathogen is identified, the remedy exists, the population is suffering. And yet the minister hesitates, citing logistics and politics. I face the identical paralysis in Rio. We know the mosquito carries yellow fever. We know how to eliminate breeding sites. But the landlords resist inspection, the press calls me a tyrant, and the politicians calculate electoral costs. Logistical challenges are real, certainly. But in my experience, when officials emphasize logistics, they are often concealing a failure of political will. The machine is ready. The hand that must pull the lever trembles.

The trembling hand — yes. I have spent my own career trembling before publication, so I sympathize more than you might expect. I delayed my principal work for twenty years, partly from scientific caution, partly from a quite reasonable fear of the storm it would provoke. But let me press you on this Turkish defense matter. What strikes me is the word integrated. This firm has combined electronic warfare, counter-aerial devices, and naval systems into a single architecture. In natural history, we observe that the most successful organisms are not those with one extraordinary adaptation but those with integrated systems — circulation, respiration, nervous response all coordinated. A bird does not merely have wings; it has hollow bones, efficient lungs, a rapid heart. Is this military integration analogous?

The analogy is powerful, and I would extend it to public health. When I campaign against yellow fever, I cannot merely kill mosquitoes. I must simultaneously reform the water supply, enforce building codes, train sanitary inspectors, maintain laboratory surveillance, and — most difficult of all — persuade the public. If any single element fails, the disease persists. This Turkish approach sounds like what I dream of for Brazilian sanitation: a unified system where each component reinforces the others. But I would offer a caution from experience. Integration demands centralized authority, and centralized authority provokes resistance. Within the year, I expect to face something approaching a revolt in Rio over precisely this question — whether the state may compel individuals to accept a coordinated public health regime. The architecture may be brilliant. The question is whether the society will tolerate it.

You anticipate revolt? That is sobering. And it connects, I think, to our final specimen: this large financial institution — Fidelity, they call it — quietly closing its venture capital operations. Now, in nature, extinction is not always dramatic. Most species do not perish in catastrophe. They simply fail to reproduce. They are outcompeted gradually, their niche occupied by better-adapted forms. A quiet exit, as the dispatch says. Dr. Cruz, does this remind you of anything in your institutional world? The slow withdrawal of a large organism from a habitat it once dominated?

It reminds me of the great hospitals of the Empire that once led Brazilian medicine and now stand half-empty, their methods obsolete, their physicians resistant to bacteriology. They do not close with announcements. They simply cease to matter. The patients go elsewhere. The talented young doctors seek positions at newer institutions. Fidelity — the name itself is almost ironic, is it not? Fidelity to what? If the environment demands speed, risk tolerance, and specialized knowledge of these new artificial intelligence technologies, then a large traditional institution may find itself as poorly adapted as a colonial hospital confronting microorganisms it refuses to acknowledge. The quiet exit is perhaps the most dignified form of extinction. But it is extinction nonetheless. I do not say this with satisfaction. I say it as a diagnostician.

A diagnostician — yes, and I suppose I am a taxonomist. Let me attempt a synthesis, though I do so with my customary hesitation. What I observe across these five specimens is a single principle expressing itself in varied forms: the environment is changing rapidly, and organisms — whether commercial ventures, military establishments, financial institutions, or excluded populations of founders — must either adapt or yield their place. The billions flowing toward artificial intelligence represent a wager on a new adaptation. The women's fund represents a belated correction of artificial constraint. The Swedish hesitation and the Turkish integration represent two different responses to the same military pressure. And Fidelity's quiet departure is natural selection operating with its usual indifference to legacy. Dr. Cruz, would you amend my classification?

I would add only one element that your natural history, magnificent as it is, sometimes underweights: human agency. In nature, the finch does not choose its beak. But we — physicians, statesmen, investors, founders — we can choose. We can choose to vaccinate or to riot. We can choose to fund the excluded or to perpetuate exclusion. We can choose to act with courage or to cite logistics while people die. The patterns you describe are real, Mr. Darwin. Selection is merciless. But I have staked my career — and perhaps, before long, my safety — on the conviction that informed human action can bend the trajectory. Not against nature, but with fuller knowledge of it. That is what a laboratory is for. That is what a vaccine is for. That is what, I dare hope, these new tools of intelligence might be for — if the hand that wields them does not tremble too long.